Our study was designed to prospectively determine whether or not unrelated cord blood transplantation (CBT) can produce outcomes comparable to related donor transplantation for children with b-thalassaemia. In 35 patients, 40 transplants were performed between October 2003 and September 2009. HLA matching at enrolment was 6/6 (n ¼ 8), 5/6 (n ¼ 16), 4/6 (n ¼ 27), or 3/6 (n ¼ 1) by low-resolution HLA-A, -B, and high-resolution DRB1. These patients received non-manipulated grafts without ex vivo expansion or T-cell depletion. The median number of nucleated and CD34 þ cells infused was 7.8 Â 10 7 /kg (range, 2.8-14.7 Â 10 7 /kg) and 4.0 Â 10 5 /kg (range, 1.7-19.9 Â 10 5 /kg), respectively. The 5-year OS and thalassaemia-free survival after the first transplant were 88.3 and 73.9%, respectively. The cumulative incidence of TRM at 2 years was 11.7%. Fourteen patients developed chronic skin GVHD. Thirty patients were alive and transfusion-independent with a Lansky performance score X80% achieved between 6 and 76 months post transplant (median, 36 months). These data compare acceptably with the survival rates of related-donor BMT for thalassaemia and suggest that patients without an available HLAcompatible sibling but who have well-matched unrelated donors should also be considered for CBT.
Introduction
A recent survey has indicated that over 330 000 infants affected by haemoglobinopathy are born annually (83% sickle-cell disorders and 17% thalassaemias), 1 and as a result of reduction in childhood mortality due to infection and malnutrition, more babies with transfusion-dependent thalassaemia will survive to present for treatment. 2, 3 Transfusions can cause major morbidity, poor quality of life, and early death from the combined effects of anaemia, haemolysis, iron overload and ineffective erythropoiesis. 4 Strategies to reduce cardiac disease by improving chelation regimens have been of the highest priority. 5 Haematopoietic SCT (HSCT) remains the only definitive curative therapy for thalassaemia and other haemoglobinopathies. The development of oral chelators has not changed this situation. [6] [7] [8] [9] To meet the increasing demand for RBCs in an era of dwindling supply, 10 there is heightened interest in providing a reliable transplant resulting in transfusion independence that is also cost-effective. Unrelated cord blood may be easier to obtain than adult BM, allowing for the treatment of more patients.
Patients and methods

Patient eligibility
In all, 35 consecutive patients with transfusion-dependent thalassaemia underwent transplantation with unrelated umbilical cord blood (UCB) units at Chang Gung Children's Hospital between October 2003 and September 2009. The clinical diagnosis of each thalassaemia patient was confirmed by DNA sequencing. No patients were splenectomized prior to transplantation. Of the total sample, 31 patients had b-thalassaemia major, 3 had b-thalassaemia/Hb E disease, and 1 had b-thalassaemia/ hereditary persistence of fetal Hb. None of the patient group had an HLA-compatible sibling donor. As we did not include routine liver biopsy in our pretransplant evaluation, we could not accurately stratify our patients according to the Pesaro risk-classification system. The median age of cord blood transplantation (CBT) was 5.5 years (range, 1.2-14.0 years) with weight between 10.7 and 36.5 kg.
The study was conducted in accordance with the principles of the Declaration of Helsinki, and the Ethics Committee of Chang Gung Memorial Hospital (protocol no. 99-2030B) approved the work and the proposed study design. For participation in the study, the child had to be accompanied by a parent or legal guardian capable of giving written informed consent. Cord blood units were selected from the same National Marrow Donor Programaffiliated UCB bank for measurement clarity. Patient and donor information was compiled and verified through the audit processes of the Center for International Blood and Marrow Transplant Research.
Cord blood selection and characteristics Units were considered initially if their HLA-A, -B, and DR phenotypes matched at least four of the patient's submitted six Ag-HLA phenotypes at a serologic or intermediate-DNA level of resolution. The compatibility of HLA-A, -B, and -DRB1 was further confirmed by PCR sequence-based typing to provide absolute HLA resolution to two digits and high-probability resolution to four digits. A single allele level mismatch at HLA-DRB1 was considered acceptable. HLA disparity between each donor unit and the recipient and between the two donor units did not necessarily have to be at the same loci. A double-unit CBT was only performed if no single UCB unit X2.5 Â 10 7 total nucleated cells per kg of recipient body weight was available. The total graft-nucleated cell dose exceeded 3.7 Â 10 7 /kg, with the one unit containing a minimum cell dose of 2.0 Â 10 7 /kg. Each unit was required to have a dose of cryopreserved CD34 þ cells of at least 1.5 Â 10 5 cells/kg, such that the total CD34 þ cell dose was X3.0 Â 10 5 cells/kg. Cord blood units were thawed by direct immersion in a water bath at 37 1C using a method modified from Rubinstein et al. protocol. 11 These cryopreservation procedures do not require graft washing before infusion to remove the cryoprotectant or the products of cell lysis. The premedication scheme included hydrocortisone and benadryl given 15-30 min before the infusion. Second units were infused within 1 h of the prior UCB infusion.
Conditioning regimen and GVHD prophylaxis
The preparative regimens consisted of oral or i.v. BU (3.5 mg/kg/day, days À9 to À6), i.v. CY (50 mg/kg/day, days À5 to À2) and equine antilymphocyte globulin (30 mg/ kg/day, days À4 to À1; Atgam, Pfizer, New York, NY, USA) or rabbit antithymocyte globulin (3 mg/kg/day, days À4 to À1; Thymoglobulin, Genzyme, Cambridge, MA, USA). After January 2007, i.v. BU was used and expected to reduce the high pharmacokinetic variability exhibited with oral BU. No hepatic venoocclusive disease prophylaxis was given. All patients received phenytoin for prophylaxis against seizures during treatment. Mesna 50 mg/kg was administered intravenously on the days of CY infusion. GVHD prophylaxis comprised CsA (2.5 mg/ kg intravenously every 8-12 h) from day À3 with a course of methylprednisolone (1 mg/kg intravenously every 12 h on days 5-19, decreasing 25% thereafter every other day). The level of CsA was adjusted to 200-400 ng/mL, as measured by radioimmunoassay. The CsA dose was tapered beginning at least 60 days after demonstrating engraftment and full-donor chimerism by STR analysis.
Twelve of the transplants consisted of double-unit grafts to attain a target total nucleated cell dose of at least 3.7 Â 10 7 /kg. High-resolution typing demonstrated that 12 donor-recipient pairs had two-loci HLA mismatches and 10 pairs had a mismatch at one locus.
Supportive care and post transplantation follow-up Granulocyte CSF (filgrastim; Kirin Brewery Co., Tokyo, Japan) 10 mg/kg/day or its equivalent was given intravenously on day 1 after transplantation and on each day thereafter until the neutrophil count remained 41.0 Â 10 9 / L for three consecutive days. Blood components were given whenever indicated to maintain Hb and platelet values 480 g/L and 20 Â 10 9 /L, respectively. For antimicrobial prophylaxis, i.v. cefazolin was given until the neutrophil counts exceeded 0.5 Â 10 9 /L, and oral fluconazole (3 mg/kg daily) was prescribed for the month preceding transplantation. I.v. or oral acyclovir and oral co-trimoxazole were given to prevent CMV reactivation and Pneumocystis jirovecii infection. Both acyclovir and co-trimoxazole were continued as prophylaxis until day 180 after transplantation and further continued until T-cell function was restored. Parenteral nutrition was provided for the duration of anorexia. I.v.Ig (500 mg/kg) was given at days À6, þ 7, þ 21, þ 35, þ 56, þ 77 and þ 98 following CBT. The standard CMV pp65 antigenaemia assay was performed in parallel. The positive results were quantified by counting the number of pp65-expressing cells per 50 000 leukocytes on the slide.
Chimerism analysis was performed by DNA amplification of informative polymorphic STR markers. Serial STR PCR confirmed the conversion from mixed chimerism to a predominantly donor profile on the day that the myeloid engraftment occurred, on days þ 42, þ 100, þ 180, þ 270 and þ 365 after transplantation and yearly thereafter. An additional test was done if clinically indicated. In patients achieving myeloid engraftment, desferrioxamine was administered at a dose of 40 mg/kg/day as a 24-h i.v. infusion if post transplant ferritin level exceeded 2500 mg/L. Phlebotomy was not routinely performed in our study, as it may stimulate host erythropoiesis after CBT and the residual recipient cells may also be stimulated.
Definitions
Myeloid engraftment was defined as three consecutive days of an ANC of X0.5 Â 10 9 /L. The last day of RBC transfusion was recorded as a day of RBC-transfusion independence. Platelet engraftment was defined as seven consecutive days of a platelet count of X20 Â 10 9 /L maintained without transfusion. TRM was defined as death related to transplant and not to relapse. OS was measured from the time of transplant until death from any cause. Thalassaemia-free survival (TFS) was calculated from the time of the transplant until thalassaemia recurrence with transfusion dependence or death from any cause.
Statistical analysis
Data were analysed using S-PLUS 2000 Professional software (Insightful Corp., Seattle, WA, USA). The cutoff date for analysis was 30 April 2010. The end points were engraftment, acute and chronic GVHD, graft failure, TRM, OS and TFS. The probabilities of TRM, OS, and TFS were evaluated by Kaplan-Meier analysis. Patients who had very slow engraftment after day 42 or failed to have marrow reconstitution of donor origin were scored as having primary graft failure.
Results
Clinical outcomes
As schematically presented in Table 1 , 35 patients had been transplanted from October 2003 to September 2009. In all, 26 patients received a single-UCB unit, whereas the remaining 9 patients received two units as their initial transplants. The cumulative engraftment rates were 70.7±7.8% after one transplant and 79.1±7.1% after two transplants, respectively. After the first transplant 28 patients had become transfusion independent. Six patients presented primary or secondary graft failure, all of whom were subsequently retransplanted. Five patients subsequently underwent second transplants with CBT (four double units and one single unit) and one received PBPC transplantation from his HLA-compatible mother; five patients had successful engraftment and transfusion independence. No patient required rescue with cryopreserved autologous backup harvests. One of these nine patients receiving 2 UCB units was retransplanted again 10 months after first transplantation for secondary graft failure.
Forty percent of the donor-recipient pairs were ABOmatched. Of the 40 single-and double-unit transplants, 35 achieved neutrophil engraftment at a median of day 17 (range, 12-33 days). The median time to achieve platelet engraftment was 46 days (range, 24-117 days). Five-year OS and TFS were 88.3 ± 6.7% and 73.9 ± 7.4%, respectively (Figure 1a) . The cumulative incidence of TRM at 2 years was 11.7 ± 6.7%. Of these patients (Figure 1b) , 30 (86%) were alive and transfusion independent with a Lansky performance score X80% achieved between 6 and 76 months post transplant (median, 36 months).
According to the criteria outlined previously, continuous chelation therapy was performed with desferrioxamine in 24 patients during the early post-transplantation period.
Transplantation-related events
Acute GVHD occurred in 34 evaluable patients and was scored as grade I (n ¼ 6), grade II (n ¼ 12), grade III (n ¼ 15) or grade IV (n ¼ 1) disease (Table 2) . Skin was the organ Cord blood transplantation for thalassaemia T-H Jaing et al The patients received second transplant for graft failure.
Cord blood transplantation for thalassaemia T-H Jaing et al most likely to be affected, with mild-to-moderate disease in the majority of patients. Chronic skin GVHD was developed in 14 patients (extensive in 1 patient and limited in 13 patients).
Clinical correlates and outcomes of this series are listed in Table 3 . Of the 35 cases, 9 had CMV reactivation post transplantation. The median time of CMV occurrence, as indicated by pp65 antigenaemia, was 39 days from the date of transplant (range, 19-134 days). All but one were successfully treated preemptively with i.v. ganciclovir.
BK virus was detected in four patients who presented with severe haemorrhagic cystitis following CBT. In addition, two patients had concomitant CMV antigenaemia and BK viraemia. Patient 23 developed late-onset haemorrhagic cystitis 24 days post transplantation associated with BK viruria concomitant with CMV reactivation. BK virus-associated haemorrhagic cystitis and simultaneous CMV reactivation were treated by stopping immunosuppressive agents after complete autologous recovery had been identified.
Bacteraemia was documented in 7 patients (20%; streptococci in 3 patients, staphylococci in 3 patients, and Acinetobacter junii in 1 patient). Staphylococcus aureus was isolated from pericardial abscesses in one case. Two patients eventually died of bacteraemia. No symptomatic cardiac dysfunction was reported in this study.
The diagnosis of post transplant autoimmune cytopenia, which occurred in 5 (14%) patients, was confirmed by a positive direct Coombs' test. The cytopenias observed included anaemia with thrombocytopenia (n ¼ 4) and pancytopenia (n ¼ 1). The median time of occurrence was 168 days (range, 85-208 days) post transplant with a median duration of 23 months (range, 18-29 months). The initial therapies included corticosteroids, CsA, i.v. Ig and 6-mercaptopurine. Four patients were subsequently treated with anti-CD20 MoAb (rituximab). Four patients had complete resolution. One patient died of diffuse alveolar haemorrhage 11 months post transplant despite rituximab treatment.
Discussion
Although blood transfusions are important for patients with haemoglobinopathies, chronic transfusions inevitably lead to iron overload as humans cannot actively remove excess iron. 12 By minimizing transfusion to lessen annual iron intake, a moderate transfusion by maintaining a Hb level of 9-10 g/dL may reduce iron loading in patients with transfusion-dependent thalassaemia without producing excessive expansion of erythropoiesis. 13 CBT offers a cure for thalassaemia and has advantages as a stem cell source because the requirement for an HLA match between donor and recipient is less stringent. Locatelli et al.
14 had reported on related CBT in 44 children with thalassaemia and sicklecell disease, and showed high engraftment rates (89% at day 60) and EFS (79% for thalassaemia and 90% for sickle-cell disease). We had thus pursued the double CBT approach when the number of cells in each UCB unit did not meet the requirements.
HSCT remains the only definitive curative therapy for thalassaemia and other haemoglobinopathies. The large Pesaro experience has demonstrated that OS and TFS after BMT from an HLA-identical donor ranged from 87 to 95%, and from 64 to 90%, respectively, depending on the Pesaro risk class. 15 In a 2006 study of 49 paediatricthalassaemia patients, the 2-year TFS estimate for recipients of related-donor stem cells was 82% compared with 71% in the unrelated-donor stem cell group (P ¼ 0.42). 16 A 2007 study of 20 thalassaemia patients received fludarabine and BU as a conditioning regimen for allogeneic HSCT from 18 HLA-matched related and 2 unrelated donors. With a median follow-up period of 39 months (range, 5-112 months) the OS was 100%, whereas TFS was 80%. 17 We also analysed outcomes after HSCT from an HLA-compatible related donor for five thalassaemia patients at our centre since 2000. All patients were alive and transfusion independent after a median follow-up of 46 months (range, 20-123 months).
Despite recent advances, there is significant TRM and morbidity associated with myeloablative transplants for haemoglobinopathies.
3 UCB has the advantages of rapid availability and low risk of severe GVHD despite donorrecipient HLA disparity. 5 The Chang Gung Paediatric HSCT Program has an active protocol for using unrelated cord blood for transplantation as an alternative source of stem cells when an HLA-compatible sibling donor is not available. The current study, using a rigid intent-to-treat statistical approach, suggested that the risks associated with HSCT would be increased by the iron overload and sensitization to HLA induced by hypertransfusion. The risk of dying of transplant-related complications has been shown to be mainly dependent on patient age, iron overload and viral liver infections. 18 Therefore, it was decided that early transplantation of unrelated cord blood could be conducted in young patients who had received few transfusions with the objective to improve the riskbenefit ratio. Autoimmune cytopenias are a recognized complication after HSCT, and are considered to be a feature of chronic GVHD when another symptom of chronic GVHD is present. 19, 20 O'Brien et al. 21 described the largest series of paediatric patients who received unrelated donor HSCT with 19 (6%) of 303 patients developing autoimmue haemolytic anaemia. It was proposed that HLA mismatches may have been a risk factor, in addition to the T-cell depletion process. Post transplant immunosuppression might interfere with normal immune ontogeny and sequentially created immune dysregulation and graftdirected cell destruction. 22 In our studies, patients with transfusion-dependent thalassaemia received unrelated CBT after immunesuppression with CY (200 mg/kg over 4 days), and BU (14 mg/kg over 4 days) was administered in the preparatory regimen for myeloablative therapy. BU is an agent that has a good possibility of eradicating a diseased erythron, but when used alone is not likely to be sufficiently immunosuppressive to permit sustained allogeneic engraftment. Furthermore, by using the same bank's products and thawing procedure described above, the quality of cord blood units could be held liable for foreseeable consequences of CBT.
This experience is characterized by two peculiarities: patients were ethnically very heterogeneous and the vast majority of these patients was not regularly transfused/ chelated, and therefore was highly sensitized due to RBC transfusions without leukodepletion filters. Consequently, they could have a high risk of graft rejection as a result of sensitization to HLA Ags. However, the issue of graft rejection is obviated by administering an extremely high or mega dose of MHC-incompatible stem cells. 23 Notably, the use of double-unit grafts as a strategy to augment graft cell dose has shown promising results. [24] [25] [26] Although improvements in conservative treatment have considerably ameliorated the prognosis of children with thalassaemia, disease-and treatment-related complications in these patients progress over time, causing severe morbidity and shortened life expectancy. 27, 28 No prospective randomized clinical trial will be able to provide a definitive answer to the challenge of choosing between HSCT and medical therapy for each individual patient. For paediatric patients, parents face an even more difficult decision. 8 Nevertheless, transplanted thalassemicpatients enjoy better quality of life, mainly in physical health, compared with conventionally treated patients. 29 Delaying transplantation until the patient is in an at-risk category substantially reduces the probability of transplant success and jeopardizes the reversibility of organ damage. This is the largest single-institution unrelated CBT series for thalassaemia, and shows the satisfactory preliminary results that are attainable when TNC dose is optimized with cord blood units, no post-thaw wash and double-unit CBT when necessary. Although the role of HSCT for thalassaemia in the era of novel iron-chelating agents is yet to be debated, manageable cutaneous GVHD tends to prefer CBT, especially in the unrelated-donor setting. Unrelated CBT using myeloablative conditioning may be a viable therapeutic approach for patients with transfusiondependent thalassaemia.
